Insulin Management in Hospitalized CKD Stage 4 Patient on Xultophy
Switch to insulin degludec 11 units subcutaneously once daily in the hospital, discontinuing the liraglutide component of Xultophy. 1
Rationale for Insulin Degludec Dosing
Your patient is taking Xultophy 11 units daily, which contains 11 units of insulin degludec and 0.396 mg of liraglutide. In the hospital setting with CKD stage 4 (eGFR 14):
- Continue the same basal insulin dose (11 units of insulin degludec) as the patient was receiving at home 2
- Discontinue the liraglutide component because GLP-1 receptor agonists should be stopped at eGFR <30 mL/min/1.73 m² 3, 4
Key Evidence Supporting This Approach
Insulin degludec pharmacokinetics are preserved in severe renal impairment. A dedicated pharmacokinetic study demonstrated that insulin degludec maintains its ultra-long pharmacokinetic properties without statistically significant differences in absorption or clearance in patients with severe renal impairment and end-stage renal disease compared to those with normal renal function 2. This means no dose adjustment is required based on renal function alone for insulin degludec.
Hospital Insulin Regimen Structure
For this hospitalized patient, implement a basal-plus approach 5:
- Basal insulin: Insulin degludec 11 units subcutaneously once daily (same time each day)
- Correctional insulin: Rapid-acting insulin (lispro, aspart, or regular) before meals or every 6 hours if NPO, using a sliding scale for glucose >180 mg/dL
The basal-plus approach is specifically recommended for hospitalized patients with decreased oral intake and those undergoing procedures 5, making it ideal for this clinical scenario.
Critical Monitoring Considerations
Hypoglycemia risk is substantially elevated in CKD stage 4 due to:
- Reduced renal insulin clearance
- Decreased gluconeogenesis
- Impaired counter-regulatory responses
- Unpredictable oral intake during hospitalization
Monitor blood glucose before meals and at bedtime (or every 6 hours if NPO). Target glucose range of 140-180 mg/dL is appropriate for most hospitalized patients 5.
Important Caveats
Do not reduce the insulin dose prophylactically unless the patient develops hypoglycemia or has significantly reduced oral intake. While some observational data suggest insulin analogue requirements may decrease with declining renal function 6, the pharmacokinetic study of insulin degludec specifically showed no need for dose adjustment 2.
If hypoglycemia occurs, reduce the basal insulin dose by 10-20% and reassess daily. The patient's home dose of 11 units is already quite modest (approximately 0.1-0.15 U/kg for an average adult), suggesting they are not at high risk for over-insulinization.
Avoid premixed insulins in the hospital setting due to unacceptably high hypoglycemia rates 5.
Transition Planning
When discharging the patient:
- Can resume Xultophy 11 units if eGFR improves to >30 mL/min/1.73 m²
- If eGFR remains <30 mL/min/1.73 m², continue insulin degludec alone and do not restart liraglutide 3
- Consider adding other glucose-lowering agents appropriate for advanced CKD (DPP-4 inhibitors with dose adjustment, or insulin intensification) 3